Accesibility | J&J withMe

Accessibility statement for www.emea.jnjwithme.com

This statement applies to content published on www.emea.jnjwithme.com.

This website is maintained by J&J Innovative Medicine which is solely responsible for its content. It is intended for visitors in Europe (excluding the UK), the Middle East and Africa. The text should be clear and simple to understand. You should be able to:

zoom in up to 300% without problems
navigate most of the website using just a keyboard
navigate most of the website using speech recognition software
use most of the website using a screen reader (including the most recent versions of JAWS, NVDA and VoiceOver)

How accessible this website is

Parts of this website are not fully accessible. For example:

some video's could have missing subtitles
some pages may consist of iFrames

Reporting accessibility problems with this website

If you find any problems that are not listed on this page or you think we’re not meeting the accessibility requirements, contact us: https://innovativemedicine.jnj.com/emea/contact-us

Compliance status

This website is partially compliant with the Web Content Accessibility Guidelines version 2.1 AA standard.

The most recent assessment was made on April 2023.

References

[1]

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.

[2]

Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.

[3]

Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.

[4]

Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.

[5]

DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.

[6]

Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.

[7]

Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.

[8]

NHS Inform. Diarrhoea. Available at: https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/diarrhoea/. Last accessed: November 2024.

[9]

Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.

[10]

Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.

[11]

Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.

[12]

Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.

Get In Touch